Blog

Increased survival claims survive validity challenge despite one prior art report of successful treatment and ongoing phase III clinical program.

Teva Pharmaceuticals fails to prove that dose reduction for mifepristone when co-administered with a strong CYP3A inhibitor would have been obvious.

Tablet that “targeted” a PK profile deemed incomprehensible

Clinical study that included patients with bone fractures satisfied claim requirement for “selecting” patient with bone fractures.

Federal Circuit affirms PTAB decision that concentration of industrial antifungal agent in toenail fungus solution would have been obvious.

Federal Circuit affirms trial court decision that dose could have been arrived at by routine experimentation.

PTAB provides two step road map for securing companion diagnostic and other biomarker-based patents.

PTAB reverses Examiner’s decision that intrathecal dose would have been arrived at by “routine optimization”

PTAB reverses Examiner’s finding of obviousness based on evidence distinguishing claimed insomnia population from insomnia population in the prior art.

Rosy predictions of cancer drug’s efficacy in a general review article did not impart reasonable expectation of success without data supporting the predictions.